Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Taxus Cardium Pharmaceuticals Group Inc. (CRXM)
OTHER OTC:CRXM
Taxus Cardium Pharmaceuticals Group (CRXM) Stock Price & Analysis
33 Followers
CRXM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.03
Volume2.00K
Average Volume (3M)N/A
Market Cap
$65.00
Enterprise Value$181.52K
Total Cash (Recent Filing)$386.03K
Total Debt (Recent Filing)$1.26M
Price to Earnings (P/E)―
Beta-26.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,931,888
10 Day Avg. Volume111
30 Day Avg. VolumeN/A
Standard Deviation26.19
R-Squared0.00305
Alpha7.11
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
6.16%
Insiders
0.00%
Mutual Funds
0.00% Other Institutional Investors
93.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CRXM FAQ
What was Taxus Cardium Pharmaceuticals Group Inc.’s price range in the past 12 months?
Currently, no data Available
What is Taxus Cardium Pharmaceuticals Group Inc.’s market cap?
Currently, no data Available
When is Taxus Cardium Pharmaceuticals Group Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Taxus Cardium Pharmaceuticals Group Inc.’s earnings last quarter?
Currently, no data Available
Is Taxus Cardium Pharmaceuticals Group Inc. overvalued?
According to Wall Street analysts Taxus Cardium Pharmaceuticals Group Inc.’s price is currently Overvalued.
Does Taxus Cardium Pharmaceuticals Group Inc. pay dividends?
Taxus Cardium Pharmaceuticals Group Inc. does not currently pay dividends.
What is Taxus Cardium Pharmaceuticals Group Inc.’s EPS estimate?
Taxus Cardium Pharmaceuticals Group Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Taxus Cardium Pharmaceuticals Group Inc. have?
Taxus Cardium Pharmaceuticals Group Inc. has 64,931,885 shares outstanding.
What happened to Taxus Cardium Pharmaceuticals Group Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Taxus Cardium Pharmaceuticals Group Inc.?
Currently, no hedge funds are holding shares in CRXM
---
Taxus Cardium Pharmaceuticals Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Taxus Cardium Pharmaceuticals Group Inc.
Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease; and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA.
---
---